Healthcare provider profile · identity verified

Henry Pinango, MD

Allopathic & Osteopathic Physicians|Internal Medicine · LIVINGSTON, MT · NPI 1427488204

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Henry Pinango, MD received $18.85 in general payments during 2025 across 1 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.85

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$18.85	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$18.85	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$18.85	1	2025
Source payment records 2025-05-07 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	149	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	149	33

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	685	219
Losartan Potassium	Losartan Potassium	435	120
Levothyroxine Sodium	Levothyroxine Sodium	432	119
Omeprazole	Omeprazole	415	128
Amlodipine Besylate	Amlodipine Besylate	397	126
Lisinopril	Lisinopril	391	117
Gabapentin	Gabapentin	361	96
Tamsulosin Hcl	Tamsulosin Hcl	355	101
Eliquis	Apixaban	308	67
Metoprolol Succinate	Metoprolol Succinate	290	89
Rosuvastatin Calcium	Rosuvastatin Calcium	218	77
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	210	39
Pantoprazole Sodium	Pantoprazole Sodium	187	52
Metformin Hcl	Metformin Hcl	186	57
Trazodone Hcl	Trazodone Hcl	184	59
Sertraline Hcl	Sertraline Hcl	183	50
Zolpidem Tartrate	Zolpidem Tartrate	159	27
Jardiance	Empagliflozin	149	33
Oxycodone Hcl	Oxycodone Hcl	149	30
Alendronate Sodium	Alendronate Sodium	148	49
Hydrochlorothiazide	Hydrochlorothiazide	147	48
Potassium Chloride	Potassium Chloride	146	45
Citalopram Hbr	Citalopram Hydrobromide	145	34
Furosemide	Furosemide	145	30
Mirtazapine	Mirtazapine	144	35
Chlorthalidone	Chlorthalidone	140	43
Fluticasone Propionate	Fluticasone Propionate	126	60
Pregabalin	Pregabalin	122	36
Allopurinol	Allopurinol	117	35
Montelukast Sodium	Montelukast Sodium	116	22
Prednisone	Prednisone	116	51
Duloxetine Hcl	Duloxetine Hcl	115	40
Buspirone Hcl	Buspirone Hcl	112	21
Spironolactone	Spironolactone	108	35
Celecoxib	Celecoxib	104	30
Albuterol Sulfate Hfa	Albuterol Sulfate	99	48
Simvastatin	Simvastatin	94	32
Pravastatin Sodium	Pravastatin Sodium	93	24
Warfarin Sodium	Warfarin Sodium	93	34
Carvedilol	Carvedilol	90	23
Metoprolol Tartrate	Metoprolol Tartrate	89	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	88	28
Xarelto	Rivaroxaban	88	21
Famotidine	Famotidine	84	23
Quetiapine Fumarate	Quetiapine Fumarate	83	14
Finasteride	Finasteride	82	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	82	25
Metformin Hcl Er	Metformin Hcl	80	28
Escitalopram Oxalate	Escitalopram Oxalate	78	19
Torsemide	Torsemide	76	30
Tramadol Hcl	Tramadol Hcl	74	13
Glipizide	Glipizide	72	14
Clopidogrel	Clopidogrel Bisulfate	67	29
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	64	13
Propranolol Hcl	Propranolol Hcl	64	18
Myrbetriq	Mirabegron	59	11
Bupropion Xl	Bupropion Hcl	58	17
Donepezil Hcl	Donepezil Hcl	58	13
Triamcinolone Acetonide	Triamcinolone Acetonide	56	32
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	53	11
Clonazepam	Clonazepam	53	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	53	suppressed
Methadone Hcl	Methadone Hcl	50	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	49	11
Ozempic	Semaglutide	49	14
Divalproex Sodium	Divalproex Sodium	47	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	47	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	45	16
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	45	suppressed
Fluconazole	Fluconazole	43	27
Glipizide Er	Glipizide	42	13
Lorazepam	Lorazepam	41	19
Farxiga	Dapagliflozin Propanediol	40	13
Ezetimibe	Ezetimibe	39	19
Methocarbamol	Methocarbamol	39	15
Lactulose	Lactulose	38	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	37	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	37	13
Acetaminophen-Codeine	Acetaminophen With Codeine	36	suppressed
Cephalexin	Cephalexin	36	19
Entresto	Sacubitril/Valsartan	36	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	36	suppressed
Ropinirole Hcl	Ropinirole Hcl	36	suppressed
Azelastine Hcl	Azelastine Hcl	35	16
Sucralfate	Sucralfate	35	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	34	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	33	16
Benazepril Hcl	Benazepril Hcl	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	16
Breo Ellipta	Fluticasone/Vilanterol	31	suppressed
Levetiracetam	Levetiracetam	31	suppressed
Solifenacin Succinate	Solifenacin Succinate	31	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Ventolin Hfa	Albuterol Sulfate	31	16
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Baclofen	Baclofen	30	suppressed
Fentanyl	Fentanyl	30	suppressed
Novolog Flexpen	Insulin Aspart	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Acyclovir	Acyclovir	28	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	28	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	28	suppressed
Terazosin Hcl	Terazosin Hcl	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Incruse Ellipta	Umeclidinium Bromide	27	suppressed
Meloxicam	Meloxicam	27	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Morphine Sulfate Er	Morphine Sulfate	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Glimepiride	Glimepiride	23	suppressed
Methylphenidate Er (La)	Methylphenidate Hcl	23	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	22	suppressed
Colchicine	Colchicine	22	12
Lantus	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Methotrexate	Methotrexate Sodium	22	suppressed
Topiramate	Topiramate	22	suppressed
Bumetanide	Bumetanide	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Morphine Sulfate	Morphine Sulfate	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	21	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Rybelsus	Semaglutide	20	suppressed
Victoza 3-Pak	Liraglutide	20	suppressed
Diazepam	Diazepam	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Atenolol	Atenolol	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Eszopiclone	Eszopiclone	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	18	suppressed
Olanzapine	Olanzapine	18	suppressed
Valsartan	Valsartan	18	suppressed
Dutasteride	Dutasteride	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Leflunomide	Leflunomide	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Nystatin	Nystatin	17	14
Ondansetron Odt	Ondansetron	17	suppressed
Testosterone Cypionate	Testosterone Cypionate	17	suppressed
Bupropion Hcl	Bupropion Hcl	16	suppressed
Bydureon Bcise	Exenatide Microspheres	16	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Repatha Sureclick	Evolocumab	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Linzess	Linaclotide	13	suppressed
Nitroglycerin	Nitroglycerin	13	12
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	12	suppressed
Estradiol	Estradiol	12	suppressed
Indomethacin	Indomethacin	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Temazepam	Temazepam	12	suppressed
Amantadine	Amantadine Hcl	11	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Chlordiazepoxide-Clidinium	Chlordiazepoxide/Clidinium Br	11	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Liothyronine Sodium	Liothyronine Sodium	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Unifine Pentips	Pen Needle, Diabetic	11	suppressed
Victoza 2-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$18.85 · 1 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error